TargetBeta
HMGB1
high mobility group box 1 · also HMG3, SBP-1, DKFZp686A04236, HMG1 · Canonical high mobility group
1 program in company-led studies act on HMGB1, from 1 company: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| HMGB1 Inhibitor SB17170rule | SPARK Biopharma | phase 2 | 42 running | – | NCIt |
Conditions their studies are in
- Idiopathic Pulmonary Fibrosis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jun 30, 2027HMGB1 Inhibitor SB17170 · SPARK Biopharma · phase 2 · NCT05522868
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.